IL5 and nasal cavity polyp: So far, some monoclonal antibodies in CRSwNP have entered clinical application or clinical trial stage to treat nasal polyps, including omalizumab (anti‐IgE), reslizumab (anti‐IL‐5), mepolizumab (anti‐IL‐5) and dupilumab (anti‐IL‐4Rα).132